3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
20
Meningioma
6
Gastro-enteropancreatic neuroendocrine tumor
6
Pheochromocytoma
3
Paraganglioma
3
Prostatic Neoplasms
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Adenoma, Islet Cell
2
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Digestive System Neuroendocrine Tumor G1
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Carcinoid Tumor
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms
×
lutetium Lu 177 dotatate
×
1 year
×
Clear all
No trials found.